Menu
BioXscience takes a careful and organized approach to developing new drugs. From the initial discovery phase through research and development, we use our extensive experience and successful early trials to reduce costs and risks in later stages. Our goal is to create effective treatments, especially for conditions caused by immune reactions.
Our current treatments for hay fever and asthma show how effective our BIRC technology is. These successes also open the door for future treatments. BIRC technology holds great potential for treating other immune-related diseases, such as inflammatory bowel diseases.
BioXscience’s organized approach ensures we can bring these new treatments to market efficiently. By focusing on the root causes of immune response diseases, we aim to provide significant health benefits and improve patients’ quality of life.
This is the essence of BioXscience’s work: developing effective, targeted treatments for immune response diseases through a careful and innovative process.
Allergic Rhinitis, commonly known as hay fever, is a widespread condition that affects millions of people, leading to symptoms such as sneezing, itching, nasal congestion, and watery eyes. Despite the prevalence of this condition, traditional treatments often fall short, providing only temporary relief and failing to address the root cause of the allergic response.
Our BIRC technology addresses this by developing treatments that tackle the disease at its source, reducing the severity of allergic responses and minimizing symptom recurrence.
Asthma is a chronic respiratory condition that affects millions of people, leading to symptoms such as wheezing, shortness of breath, chest tightness, and coughing. Despite the availability of various treatments, many traditional approaches only manage the symptoms without effectively targeting the underlying causes of the disease.
At BioXscience, we are transforming the treatment of Asthma through our groundbreaking BIRC technology. What makes BIRC unique is its ability to reconfigure bioactive components at the molecular level, enabling the development of medications that precisely target the intracellular pathways involved in the inflammatory and immune responses that drive Asthma.
This approach goes beyond merely controlling symptoms; it aims to address the root causes of the condition at the cellular level.
Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disorder that causes airflow limitation, leading to persistent breathing difficulties and a reduced quality of life. The damage to the airways and lung tissue results in symptoms such as chronic cough, excessive mucus production, fatigue, and breathlessness. Effective treatment of COPD requires more than conventional inhalers; it demands innovation that targets the disease at its core.
Bioxscience is at the forefront of this innovation with our unique BIRC technology. BIRC stands apart by focusing on reconfiguring bioactive components at the molecular level, allowing us to develop therapies that directly target the root causes of COPD. By precisely modulating the intracellular pathways responsible for inflammation and tissue damage, our technology goes beyond symptom relief, it seeks to restore lung function and address the underlying cellular dysfunctions that drive disease progression.